Jiudian Pharmaceutical signed a patent and technology transfer agreement for LPS/CD 14 dual-target spot polypeptide new drug with Zonsen Peplib Biotech.

Release time:

2024-02-29 14:20

Source:

Abstract

Jiudian Pharmaceutical signed a patent and technology transfer agreement for LPS/CD 14 dual-target spot polypeptide new drug with Zonsen PepLib Biotech in Changsha China on Feb 28, 2024.

The total transaction volume of the cooperation agreement is more than 560 million RMB, and the initial payment is 15 million RMB.

The polypeptide drug above-mentioned has the dual function of antibacterial and anti-inflammatory.

From this agreement, Jiudian Pharmaceutical have the exclusive rights to develop, produce and commercialize the above polypeptide drug candidates in the world. And we have the same rights in the field of cosmetic medicine and others.

It is a big step in the development of polypeptide drugs for Hunan Jiudian Pharmaceutical Co., Ltd.

Hunan Jiudian Pharmaceutical have Ecovadis Bronze at the beginning of 2024

Hunan Jiudian Pharmaceutical have Market Authorization of dapoxetine hydrochloride, celecoxib and Nicorandil API from NMPA

Hunan Jiudian Pharmaceutical have Ecovadis Bronze at the beginning of 2024

Hunan Jiudian Pharmaceutical have Market Authorization of dapoxetine hydrochloride, celecoxib and Nicorandil API from NMPA

Recently, Ibuprofen Sustained-Release Capsules of Jiudian Pharmaceutical officially received a drug registration approval from the National Medical Products Administration (NMPA) and successfully passed the generic drug consistency evaluation. As a product on the National Essential Medicines List, a Class B product under the National Reimbursement Drug List, a product included in national volume-based procurement, and a nonsteroidal anti-inflammatory drug recommended as first-line therapy in clinical practice, its successful launch marks a further expansion of Jiudian Pharmaceutical's product portfolio in analgesia and anti-inflammation.

09-21

2026

Ibuprofen Sustained-Release Capsules Approved for Marketing: Analgesic and Anti-inflammatory Portfolio Further Expanded

Lacidipine Tablets Approved for Marketing: Jiudian Adds Another Major Product in the Treatment of Hypertension

Recently, Lacidipine Tablets of Jiudian Pharmaceutical officially received a drug registration approval from the National Medical Products Administration (NMPA) and successfully passed the generic drug consistency evaluation. As a third-generation, highly lipophilic, long-acting calcium channel blocker (CCB), the successful approval of this product marks an important step by Jiudian Pharmaceutical in the treatment of cardiovascular and cerebrovascular diseases and further enriches the company's product pipeline.

09-17

2026

Lacidipine Tablets Approved for Marketing: Jiudian Adds Another Major Product in the Treatment of Hypertension

Jiudian Pharmaceutical Listed Again among Hunan's Top 100 Manufacturing Enterprises, with Its Ranking Continuing to Rise

On June 5, the Conference on Advancing the Building of an Advanced Manufacturing Highland in Hunan Province was held in Changsha. The 2025 Hunan Top 100 Enterprises list, the 2025 Hunan Top 100 Manufacturing Enterprises list, and other rankings were officially released at the conference. On the strength of its manufacturing capability and operating performance, Jiudian Pharmaceutical was named to the Top 100 Manufacturing Enterprises in Hunan, ranking 75th, and maintained its momentum of consecutive listings with a steady rise in ranking.

09-15

2026

Jiudian Pharmaceutical Listed Again among Hunan's Top 100 Manufacturing Enterprises, with Its Ranking Continuing to Rise

Hunan Jiudian

Bldg A1, Wukuang Lugu Science and Technology Industry Park, No.28 Lutian Road, Hi-tech development zone, Changsha, Hunan, China TEL. 0086-731-88220222

1

Business license